Clinical Study

A Phase III Randomized Study Of Oral Sapacitabine In Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Posted Date: May 15, 2019

  • Investigator: Stephen Medlin
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to learn that among several drug options, which one is more likely to keep patients cancer in check as long as possible. This Phase III study assesses an experimental anti-cancer drug called sapacitabine and a marketed anti-cancer drug called decitabine. Decitabine has

Criteria:

To Be Eligible For This Study, Patients Must Have Acute Myeloid Leukemia (Aml)

Keywords:

Leukemia, Aml, Cancer, Hematology, Cyc682-12

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.